skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Zach McLellan & Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including analysis on Allogene's announcement that they are in-licensing the TALEN technology from Pfizer to commericalise and develop allogeneic, potentially leading to a strong acceleration of CART therapies.

Topics covered in this episode include:
  • Allogene in-licenses TALEN (originally developed by Cellectis) technology from Pfizer (CLLS PFE) - 0:30
  • New data for NeuVax/Herceptin combination in breast cancer (SLS RHHBY)- 10:45
  • MediciNova announces early termination of Phase 2 trial of MN-001 in NASH/NAFLD based on positive data (MNOV) - 17:40

Subscribe to this podcast here

 

 

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free   : +1 888 670 8900  
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (20) 805 20700

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
Contact Customer Services

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now